Coronavirus’s target might point to a Covid-19 treatment
Scientists now understand how the novel coronavirus worms its way into human cells. But a closer look at that infiltration has led researchers to what could be a path to treating Covid-19, one that would protect patients from the worst symptoms while their bodies clear the virus.
Coronavirus latches onto an enzyme called ACE2, which plays a role in mediating vascular function. When patients get Covid-19, ACE2 can’t do its crucial job of producing an anti-inflammatory peptide, which might explain the often deadly immune reaction the disease brings about. What if, researchers wondered, you could inject patients with that peptide to correct for the coronavirus’s effects?
That’s where Constant Therapeutics, a small, private biotech company, enters the picture. Constant had been developing an intravenous version of the peptide for a few rare diseases before Covid-19 came along. As the pandemic spread, the company linked up with like-minded academics. Now it’s poised to test the idea in clinical trials.
Read more.
Coronavirus latches onto an enzyme called ACE2, which plays a role in mediating vascular function. When patients get Covid-19, ACE2 can’t do its crucial job of producing an anti-inflammatory peptide, which might explain the often deadly immune reaction the disease brings about. What if, researchers wondered, you could inject patients with that peptide to correct for the coronavirus’s effects?
That’s where Constant Therapeutics, a small, private biotech company, enters the picture. Constant had been developing an intravenous version of the peptide for a few rare diseases before Covid-19 came along. As the pandemic spread, the company linked up with like-minded academics. Now it’s poised to test the idea in clinical trials.
Read more.
.png)
No hay comentarios:
Publicar un comentario